Nano CD5-CAR T cells for relapsed T-cell leukemia or lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that carry a marker called CD5. It is for people with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 70 years old.
- You have been diagnosed with CD5-positive relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
- You are feeling well enough to carry out daily activities (ECOG performance status 0-2).
- Your organs (kidneys, liver, heart, lungs) are working well enough.
- You are able to understand and sign an informed consent form.
- You do not have active severe infections, uncontrolled sepsis, severe autoimmune disease, or immunodeficiency.
- You have not had an allogeneic stem cell transplant in the last 3 months.
- You have not received prior CD5-targeted therapy.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.